Ultragenyx Pharmaceutical Inc.RARENASDAQ
LOADING
|||
Year-over-year net income growth rate
| Period | Value |
|---|---|
| Q3 2025 | -56.95% |
| Q2 2025 | 23.91% |
| Q1 2025 | -13.27% |
| Q4 2024 | 0.10% |
| Q3 2024 | -1.46% |
| Q2 2024 | 22.90% |
| Q1 2024 | -38.55% |
| Q4 2023 | 22.84% |
| Q3 2023 | 0.11% |
| Q2 2023 | 2.53% |
| Q1 2023 | -7.99% |
| Q4 2022 | 38.05% |
| Q3 2022 | -54.97% |
| Q2 2022 | -3.84% |
| Q1 2022 | -24.39% |
| Q4 2021 | -67.76% |
| Q3 2021 | 40.37% |
| Q2 2021 | 10.07% |
| Q1 2021 | -466.99% |
| Q4 2020 | 65.12% |
| Q3 2020 | -371.95% |
| Q2 2020 | 121.27% |
| Q1 2020 | -26.89% |
| Q4 2019 | 16.98% |
| Q3 2019 | -13.94% |
| Q2 2019 | -2.50% |
| Q1 2019 | -10.17% |
| Q4 2018 | -0.59% |
| Q3 2018 | -65.59% |
| Q2 2018 | -274.29% |
| Q1 2018 | 137.02% |
| Q4 2017 | -3.16% |
| Q3 2017 | -8.69% |
| Q2 2017 | -6.74% |
| Q1 2017 | 4.20% |
| Q4 2016 | -9.83% |
| Q3 2016 | -14.03% |
| Q2 2016 | -7.90% |
| Q1 2016 | 4.46% |
| Q4 2015 | -40.75% |